NextUp: 5 Philly Biotech and Pharma Companies to Watch in 2020
From pivotal clinical trials to major partnerships, these five Philly companies made the most of 2019. Here's what they've got planned for 2020.
Philadelphia’s healthcare innovation scene won’t slow down in 2020. The region’s biotech and life sciences companies are positioned for major growth and more breakthroughs. Here are five companies poised to lead the charge.
1. Zynerba Pharmaceuticals
Zynerba is a clinical-stage pharmaceutical company working to commercialize its patented CBD gel treatment, Zygel, to treat several rare and near rare neuropsychiatric disorders like autism.
In the first half of 2020, the company hopes to have top-line data from one of several clinical trials underway to test the efficacy of its lead product and plans to submit a new drug application to the Food and Drug Administration (FDA) by the end of 2020. Read more about Zynerba here.
2. DriQ Health
Startup DriQ Health invented a smart diaper monitoring system to help manage urinary incontinence among adults in long-term care. The company is fine-tuning the product and expects to bring it to market in the first half of 2020. The monitoring system is also pending approval from the FDA. Read more about DriQ Health here.
3. Scout Bio
Biotechnology company Scout Bio is working to create gene therapy treatments for common health conditions in pets, including anemia, kidney disease, chronic pain, and atopic dermatitis. If all goes well in upcoming pivotal studies, the company could have a first-of-its-kind treatment up for FDA approval by mid-2020. Read more about Scout Bio here.
4. Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company that is developing anti-hormonal therapies for hormone-driven gynecologic and breast cancers.
In early 2020, Context will team up with the Sidney Kimmel Cancer Center at Thomas Jefferson University for a Phase II clinical trial to test a new treatment for patients with metastatic endometrial cancer who have failed multiple prior therapies. Read more about Context here.
Genomind is a biotechnology company using genetic testing and data to improve treatment decisions in psychiatry. The company’s flagship Professional PGx Express testing service examines patient-specific genetic markers that can identify treatments that are more likely to work as intended, not have an effect, or cause a negative effect.
In 2020, the company’s genetic testing service will be available in Acme pharmacies across Pennsylvania. Read more about Genomind here.